OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundance

By afschroeder • January 28, 2026

Bernard MJ, Gallardo A, Ruiz A, Diaz JA, Nunley NM, Dove RN, Zhang S, Lee E, Heering KY, Varuzhanyan G, Bopardikar S, Hashimoto T, Agrawal R, Smith CM, Wilde BR, Matulionis N, Richards HM, Lee SCS, Sharifi MN, Lang JM, Zhao SG, Witte ON, Haffner MC, Shackelford DB, Boutros PC, Christofk HR, Goldstein AS. OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundance. Mol Cancer Res. 2026 Jan 27. doi: 10.1158/1541-7786.MCR-25-0913. Epub ahead of print. PMID: 41591383.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

Rebuilding the foundation: recommendations from the Summit to Revitalize Primary Care (Rev PC)

Summit to Revitalize Primary Care Writing Committee*; Jerant A, Kravitz RL, Fenton JJ, Lyles CR, Grumbach K, Henderson MC, Ritley D, Brandt M, Cohen D,[...]

Hepatocyte growth factor may contribute to male protection against pulmonary arterial hypertension

Medzikovic L, Ruffenach G, Dehghanitafti A, Wong B, Ryder A, Hatamnejad MR, Sun W, Esdin L, Eghbali J, Brownstein A, Razee A, Umar S, Hong[...]